DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France
Copyright policy )DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France
AbstractWe evaluated the effect of DMTs on Covid‐19 severity in patients with MS, with a pooled‐analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid‐19 severity was assessed by multivariate ordinal‐logistic models and pooled by a fixed‐effect meta‐analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti‐CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid‐19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled‐analysis confirms an increased risk of severe Covid‐19 in patients on anti‐CD20 therapies and supports the protective role of interferon.
- Université de Montpellier (EPE) France
- Sorbonne University France
- Assistance Publique -Hopitaux De Paris France
- Sorbonne Paris Cité France
- University Federico II of Naples Italy
Adult, Male, adult; antibodies; monoclonal; humanized; covid-19; female; france; humans; immunologic factors; interferons; italy; male; meta-analysis as topic; middle aged; multiple sclerosis; multivariate analysis; protective factors; retrospective studies; risk factors; rituximab; severity of illness index, Multiple Sclerosis, 330, 610, Neurosciences. Biological psychiatry. Neuropsychiatry, Adult; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/pharmacology; COVID-19/epidemiology; COVID-19/physiopathology; Female; France/epidemiology; Humans; Immunologic Factors/adverse effects; Immunologic Factors/pharmacology; Interferons/adverse effects; Interferons/pharmacology; Italy/epidemiology; Male; Meta-Analysis as Topic; Middle Aged; Multiple Sclerosis/drug therapy; Multiple Sclerosis/epidemiology; Multivariate Analysis; Protective Factors; Retrospective Studies; Risk Factors; Rituximab/adverse effects; Rituximab/pharmacology; Severity of Illness Index, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Antibodies, Adult; Antibodies, Monoclonal, Humanized; COVID-19; Female; France; Humans; Immunologic Factors; Interferons; Italy; Male; Meta-Analysis as Topic; Middle Aged; Multiple Sclerosis; Multivariate Analysis; Protective Factors; Retrospective Studies; Risk Factors; Rituximab; Severity of Illness Index, Immunologic Factor, Meta-Analysis as Topic, Retrospective Studie, Risk Factors, Monoclonal, Multiple Sclerosi, Humans, Immunologic Factors, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], RC346-429, Humanized, Multivariate Analysi, Protective Factor, Retrospective Studies, Risk Factor, COVID-19, Middle Aged, Protective Factors, [SDV] Life Sciences [q-bio], Settore MED/26 - NEUROLOGIA, Italy, Multivariate Analysis, Interferon, Female, Neurology. Diseases of the nervous system, France, Interferons, Brief Communications, Rituximab, Human, RC321-571
Adult, Male, adult; antibodies; monoclonal; humanized; covid-19; female; france; humans; immunologic factors; interferons; italy; male; meta-analysis as topic; middle aged; multiple sclerosis; multivariate analysis; protective factors; retrospective studies; risk factors; rituximab; severity of illness index, Multiple Sclerosis, 330, 610, Neurosciences. Biological psychiatry. Neuropsychiatry, Adult; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/pharmacology; COVID-19/epidemiology; COVID-19/physiopathology; Female; France/epidemiology; Humans; Immunologic Factors/adverse effects; Immunologic Factors/pharmacology; Interferons/adverse effects; Interferons/pharmacology; Italy/epidemiology; Male; Meta-Analysis as Topic; Middle Aged; Multiple Sclerosis/drug therapy; Multiple Sclerosis/epidemiology; Multivariate Analysis; Protective Factors; Retrospective Studies; Risk Factors; Rituximab/adverse effects; Rituximab/pharmacology; Severity of Illness Index, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Antibodies, Adult; Antibodies, Monoclonal, Humanized; COVID-19; Female; France; Humans; Immunologic Factors; Interferons; Italy; Male; Meta-Analysis as Topic; Middle Aged; Multiple Sclerosis; Multivariate Analysis; Protective Factors; Retrospective Studies; Risk Factors; Rituximab; Severity of Illness Index, Immunologic Factor, Meta-Analysis as Topic, Retrospective Studie, Risk Factors, Monoclonal, Multiple Sclerosi, Humans, Immunologic Factors, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], RC346-429, Humanized, Multivariate Analysi, Protective Factor, Retrospective Studies, Risk Factor, COVID-19, Middle Aged, Protective Factors, [SDV] Life Sciences [q-bio], Settore MED/26 - NEUROLOGIA, Italy, Multivariate Analysis, Interferon, Female, Neurology. Diseases of the nervous system, France, Interferons, Brief Communications, Rituximab, Human, RC321-571
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).103 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!